Compare · DFTX vs NAGE
DFTX vs NAGE
Side-by-side comparison of Definium Therapeutics Inc. (DFTX) and Niagen Bioscience Inc. (NAGE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DFTX and NAGE operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $6.02B, about 23.3x NAGE ($258.7M).
- Over the past year, DFTX is up 345.8% and NAGE is down 67.2% - DFTX leads by 413.0 points.
- DFTX has been more active in the news (16 items in the past 4 weeks vs 8 for NAGE).
- DFTX has more recent analyst coverage (7 ratings vs 1 for NAGE).
PerformanceDFTX+345.79%NAGE-67.18%
2025-08-26+0.00%2026-08-26
- Company
- Definium Therapeutics Inc.
- Niagen Bioscience Inc.
- Price
- -
- -
- Market cap
- $6.02B
- $258.7M
- 1M return
- +5.92%
- +0.15%
- 1Y return
- +345.79%
- -67.18%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 16
- 8
- Recent ratings
- 7
- 1
Latest DFTX
- Definium Therapeutics to Participate at Upcoming Investor Conferences and Events
- BofA Securities initiated coverage on Definium Therapeutics with a new price target
- Definium Therapeutics Announces New Employee Inducement Grants
- Amendment: SEC Form SCHEDULE 13G/A filed by Definium Therapeutics Inc.
- Chief Commercial Officer Wiley Matthew T. was granted 62,500 shares, increasing direct ownership by 36% to 237,133 units (SEC Form 4)
- Chief Medical Officer Karlin Daniel was granted 100,000 shares, increasing direct ownership by 20% to 603,282 units (SEC Form 4)
- Chief Financial Officer Roberts Brandi was granted 62,500 shares, increasing direct ownership by 30% to 271,987 units (SEC Form 4)
- Chief Executive Officer Barrow Robert was granted 375,000 shares, increasing direct ownership by 34% to 1,473,246 units (SEC Form 4)
- Chief Legal Officer Sullivan Mark was granted 62,500 shares, increasing direct ownership by 19% to 383,071 units (SEC Form 4)
- Definium Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Latest NAGE
- Niagen Bioscience to Present at Nasdaq X LD Micro Inaugural SF Summit
- Niagen Bioscience Expands Tru Niagen® Retail Footprint with GNC and Sam’s Club
- Niagen Bioscience to Present at the 17th Annual Midwest IDEAS Investor Conference
- Niagen Bioscience Launches Tru Niagen on Walmart.com, Expanding Access and Diversifying Its E-commerce Marketplace Presence
- SEC Form 10-Q filed by Niagen Bioscience Inc.
- Niagen Bioscience Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Niagen Bioscience, Inc. Reports Second Quarter 2026 Financial Results
- Niagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168
- Niagen Bioscience Announces a Newly Published Analysis of Past Clinical Studies Demonstrating Niagen® (Patented Nicotinamide Riboside, NR) Supplementation Improved a Muscle-Specific Marker of Biological Aging
- Niagen Bioscience to Present at Canaccord Genuity’s 46th Annual Growth Conference